Analytical Data
-
Gene name
CCNO
- Application
-
Alternative Names
CCNO; CCNO_HUMAN; CCNU; Cyclin domain containing; Cyclin like uracil DNA glycosylase; Cyclin O; Cyclin U; Cyclin-O; DGU; EC 3.2.2.; UDG2; UNG2; Uracil DNA glycolylase 2; Uracil DNA glycosylase cyclin like
-
Species
Human
-
Source
E. coli
-
Tag
GST-tag at N-terminal
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P22674
-
Expression Region
1-350aa
-
AA Sequence
MVTPCPTSPSSPAARAGRRDNDQNLRAPVKKSRRPRLRRKQPLHPLNPCPLPGDSGICDLFESPSSGSDGAESPSAARGGSPLPGPAQPVAQLDLQTFRDYGQSCYAFRKAQESHFHPREALARQPQVTAESRCKLLSWLIPVHRQFGLSFESLCLTVNTLDRFLTTTPVAADCFQLLGVTSLLIACKQVEVHPPRVKQLLALCCGAFSRQQLCNLECIVLHKLHFTLGAPTISFFLEHFTHARVEAGQAEASEALEAQALARGVAELSLADYAFTSYSPSLLAICCLALADRMLRVSRPVDLRLGDHPEAALEDCMGKLQLLVAINSTSLTHMLPVQICEKCSLPPSSK
-
Molecular Weight
64.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCNO, or Cyclin C, is a crucial protein that plays a significant role in cell cycle regulation and transcriptional control. Recent studies have highlighted its involvement in various cellular processes, including the regulation of gene expression and the transition between different phases of the cell cycle. Abnormalities in CCNO expression can lead to several diseases, including cancer, making it a vital target for therapeutic research. The study of recombinant CCNO proteins has gained momentum as researchers seek to understand its structural and functional properties in greater detail. By utilizing recombinant DNA technology, scientists can produce CCNO in bacterial or eukaryotic systems, allowing for large-scale purification and characterization. These studies aim to elucidate the mechanisms by which CCNO interacts with other cellular proteins and its role in oncogenesis. Understanding the functional dynamics of CCNO through recombinant protein studies can pave the way for the development of novel cancer therapeutics and contribute to the broader field of cell cycle research. Additionally, elucidating the post-translational modifications and interactions of CCNO with various signaling pathways can provide insights into its multifaceted role in cellular functions. As a significant player in cell biology, CCNO continues to be a focus of intense research, promising advancements in our understanding of cell cycle control and the molecular underpinnings of cancer.
